Exploring the Metformin Addition in Prostate Cancer Therapy

This chapter delves into the findings of the Stampede trial, which explores the effects of adding metformin to androgen deprivation therapy for patients with metastatic castrate-sensitive prostate cancer. While improvements in metabolic parameters were observed, the study highlights the need for ongoing evaluation of metabolic effects in the context of enhanced cancer treatments.